User profiles for Joerg Lippert

Jörg Lippert

Bayer AG
Verified email at bayer.com
Cited by 3946

[HTML][HTML] A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular …

…, J Solodenko, K Thelen, S Willmann, J Lippert - Frontiers in …, 2011 - frontiersin.org
Today, in silico studies and trial simulations already complement experimental approaches
in pharmaceutical R&D and have become indispensable tools for decision making and …

A physiological model for the estimation of the fraction dose absorbed in humans

…, W Schmitt, J Keldenich, J Lippert… - Journal of medicinal …, 2004 - ACS Publications
A physiologically based model for gastrointestinal transit and absorption in humans is presented.
The model can be used to study the dependency of the fraction dose absorbed (F abs ) …

[HTML][HTML] Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis

…, L Bergfeld, D Hillus, JD Lippert… - Frontiers in …, 2021 - frontiersin.org
Patients with kidney failure have notoriously weak responses to common vaccines. Thus,
immunogenicity of novel SARS-CoV-2 vaccines might be impaired in this group. To determine …

From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools

S Willmann, J Lippert, W Schmitt - Expert opinion on drug …, 2005 - Taylor & Francis
During the past decade, the pharmaceutical industry has invested considerably in technologies
that have the potential to increase throughput in discovery projects. For large compound …

Trade in live reptiles, its impact on wild populations, and the role of the European market

…, K Kanari, M Krvavac, M Lettink, J Lippert… - Biological …, 2016 - Elsevier
Of the 10,272 currently recognized reptile species, the trade of fewer than 8% are regulated
by the Convention on International Trade in Endangered Species of Wild Fauna and Flora (…

Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling

…, S Schneckener, B Ludewig, L Kuepfer, J Lippert - Drug Metabolism and …, 2012 - ASPET
Active processes involved in drug metabolization and distribution mediated by enzymes,
transporters, or binding partners mostly occur simultaneously in various organs. However, a …

Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs

…, M Sevestre, J Solodenko, W Weiss, J Lippert… - … of pharmacokinetics and …, 2007 - Springer
In clinical development stages, an a priori assessment of the sensitivity of the pharmacokinetic
behavior with respect to physiological and anthropometric properties of human (sub-) …

[PDF][PDF] PK-Sim®: a physiologically based pharmacokinetic 'whole-body'model

S Willmann, J Lippert, M Sevestre, J Solodenko, F Fois… - Biosilico, 2003 - researchgate.net
Jörg Lippert, Michael Sevestre, Juri Solodenko, BAYER AG, Bayer Technology Services,
Computational Solutions, 51368 Leverkusen, Germany. Franco Fois, Walter Schmitt, BAYER …

[HTML][HTML] Smart medical information technology for healthcare (SMITH)

…, A Henkel, T Kirsten, T Klöss, J Lippert… - … of information in …, 2018 - thieme-connect.com
Introduction: This article is part of the Focus Theme of Methods of Information in Medicine
on the German Medical Informatics Initiative. “Smart Medical Information Technology for …

Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions

…, R Burghaus, JB Dressman, J Lippert - Journal of …, 2011 - Elsevier
To enable more precise prediction of oral drug absorption, an existing physiologically based
absorption model was revised. The revised model reflects detailed knowledge of human …